Skip to main content

Stargardt's Macular Dystrophy

2
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
4 programs
2
MA09-hRPEPhase 1/22 trials
MA09-hRPEPhase 1/21 trial
MA09-hRPEN/A1 trial
hESC-RPEN/A1 trial
Active Trials
NCT02445612Completed13Est. Jun 2019
NCT02941991Completed12Est. Oct 2019
NCT02563782Withdrawn0Est. May 2017
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasMA09-hRPE
AstellasMA09-hRPE
AstellasMA09-hRPE
AstellashESC-RPE
AstellasMA09-hRPE

Clinical Trials (5)

Total enrollment: 50 patients across 5 trials

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

Start: Aug 2015Est. completion: May 20170
Phase 2Withdrawn

Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Start: Dec 2011Est. completion: Sep 201512 patients
Phase 1/2Completed

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

Start: Jun 2011Est. completion: Aug 201513 patients
Phase 1/2Completed

A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Start: Jan 2013Est. completion: Oct 201912 patients
N/ACompleted

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Start: Jul 2012Est. completion: Jun 201913 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.